You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
McKinsey
Moodys
Johnson and Johnson
Express Scripts

Last Updated: February 27, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,119,781


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,119,781 protect, and when does it expire?

Patent 9,119,781 protects ENSTILAR and is included in one NDA.

Protection for ENSTILAR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-six patent family members in twenty-five countries.

Summary for Patent: 9,119,781
Title:Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Abstract: The present invention relates to a topical spray composition comprising a biologically active vitamin D derivative and a corticosteroid, and its use in the treatment of dermal diseases and conditions. The spray comprises especially a propellant selected from the group consisting of dimethyl ether, diethyl ether and methylethyl ether or a mixture thereof and further a pharmaceutically acceptable lipid carrier solubilised or suspended in said propellant.
Inventor(s): Lind; Marianne (Bagsv.ae butted.rd, DK), Rasmussen; Gritt (Virum, DK), Sonne; Mette Rydahl (Brondby Strand, DK), Hansen; Jens (Virum, DK), Petersson; Karsten (Ballerup, DK)
Assignee: LEO PHARMA A/S (Ballerup, DK)
Application Number:13/703,214
Patent Claim Types:
see list of patent claims
Composition; Compound; Use;

Drugs Protected by US Patent 9,119,781

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Leo Pharma As ENSTILAR betamethasone dipropionate; calcipotriene AEROSOL, FOAM;TOPICAL 207589-001 Oct 16, 2015 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,119,781

PCT Information
PCT FiledJune 10, 2011PCT Application Number:PCT/DK2011/000060
PCT Publication Date:December 15, 2011PCT Publication Number: WO2011/154004

International Family Members for US Patent 9,119,781

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2011264198   Start Trial
Brazil 112012030653   Start Trial
Canada 2800181   Start Trial
China 102939078   Start Trial
Cyprus 1115991   Start Trial
Denmark 2579852   Start Trial
European Patent Office 2579852   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
McKesson
Colorcon
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.